AREDS2 vs the Original AREDS Formula: What Changed and Why

The two formulas differ in one ingredient. That sounds minor and it is not, because of why the swap happened. Both came out of a pair of government trials with the same name as the formula, which is the source of most of the confusion here.

What the first trial established

The original Age-Related Eye Disease Study, run by the US National Eye Institute, was a large randomised trial that asked whether a high-dose antioxidant and zinc combination could slow age-related macular degeneration.

It found that it could, in a specific group. Among people with intermediate AMD, or advanced AMD in one eye, the formulation reduced the risk of progressing to advanced disease by around 25%, and reduced the risk of losing central vision by about 19%. For people with no AMD or only very early changes, it did nothing measurable.

That result is the foundation everything since rests on, and its narrowness is the part most often lost. It has never been a general eye vitamin, and it was never shown to prevent AMD from starting.

Then the beta-carotene problem arrived

Beta-carotene is a vitamin A precursor. It is what makes carrots orange, it is an antioxidant, and in food it is completely unremarkable. Putting it in the formula was an obvious call at the time.

At supplement doses it turned out to behave differently. Large trials investigating beta-carotene for cancer prevention found the opposite of what was expected: in smokers, high-dose beta-carotene was associated with an increased risk of lung cancer. The finding was robust enough to change practice, and it left the AREDS formula carrying an ingredient that a substantial share of its target population should not take.

This is worth sitting with, because it is the strongest argument against the reasoning that sells most supplements. The logic that put beta-carotene in the formula, that it is an antioxidant found in healthy food, is exactly the logic used to sell dozens of products today. It was reasonable. It was also wrong in a way nobody predicted from first principles.

What AREDS2 actually tested

The second trial, which reported in 2013, was designed to answer several questions at once rather than just make the substitution.

1. 01Can lutein and zeaxanthin replace beta-carotene? Yes. The substituted formulation performed at least as well, and the two carotenoids have a more direct rationale than beta-carotene ever did, since they are the pigments the macula physically concentrates.
2. 02Does removing beta-carotene cost anything? No. Effectiveness held. This is the finding that made the change straightforward rather than a trade-off.
3. 03Does a lower zinc dose work as well? Yes. Reducing zinc from 80 mg to 25 mg made no difference to the result. The investigators had hoped the lower dose would also reduce side effects such as stomach upset, and the trial did not show that either.
4. 04Does adding omega-3 help? No. Adding DHA and EPA produced no additional benefit. This is unusually clean negative evidence, and it is why omega-3 is not part of the formulation despite appearing on many eye supplements.

Which formula applies to you

In practical terms the question is mostly settled. AREDS2 is the current formulation and there is no reason to seek out the original.

Beyond that, the choice between products comes down to whether a given label reproduces the tested formulation, which is a different exercise from picking a brand. We go through what to actually check and what each ingredient is doing separately.

And the prior question has not changed across either trial: both found benefit only in people who already have intermediate AMD, or advanced AMD in one eye. If that is not you, neither formula has anything to offer.